pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati
Company profile
Ticker
PDSB
Exchange
Website
CEO
Frank Bedu-Addo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Edge Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
PDS Operating Corporation ...
PDSB stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
18 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
27 Mar 24
8-K
Patent for composition of matter and use of Infectimune® based influenza vaccines granted in the United States
13 Mar 24
8-K
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
22 Jan 24
8-K
Other Events
4 Dec 23
8-K
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
28 Nov 23
S-8
Registration of securities for employees
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
Transcripts
PDSB
Earnings call transcript
2023 Q3
14 Nov 23
PDSB
Earnings call transcript
2023 Q2
14 Aug 23
PDSB
Earnings call transcript
2023 Q1
15 May 23
PDSB
Earnings call transcript
2022 Q4
28 Mar 23
PDSB
Earnings call transcript
2022 Q3
14 Nov 22
PDSB
Earnings call transcript
2022 Q2
8 Aug 22
PDSB
Earnings call transcript
2022 Q1
11 May 22
PDSB
Earnings call transcript
2021 Q4
31 Mar 22
PDSB
Earnings call transcript
2021 Q3
10 Nov 21
PDSB
Earnings call transcript
2021 Q2
12 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 54.25 mm | 54.25 mm | 54.25 mm | 54.25 mm | 54.25 mm | 54.25 mm |
Cash burn (monthly) | 2.12 mm | 1.45 mm | 3.62 mm | 4.38 mm | 2.39 mm | 2.73 mm |
Cash used (since last report) | 14.65 mm | 10.00 mm | 24.94 mm | 30.23 mm | 16.50 mm | 18.80 mm |
Cash remaining | 39.60 mm | 44.26 mm | 29.31 mm | 24.03 mm | 37.75 mm | 35.45 mm |
Runway (months of cash) | 18.6 | 30.5 | 8.1 | 5.5 | 15.8 | 13.0 |
Institutional ownership, Q2 2021
8.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 2 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 29.46 mm |
Total shares | 3.09 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Hirschman Orin | 1.75 mm | $16.10 mm |
NSCI Netscientific | 1.34 mm | $13.36 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Jan 24 | Kirk V. Shepard | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.49 | 200,000 | 898.00 k | 200,000 |
4 Dec 23 | Lars Boesgaard | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 5.28 | 200,000 | 1.06 mm | 200,000 |
14 Jul 23 | Ilian Iliev | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 5.13 | 9,000 | 46.17 k | 9,000 |
News
PDS Biotech To Event To Discuss Positive, Updated Data From Phase 2 VERSATILE-002 Clinical Trial With Versamune HPV In Combination With KEYTRUDA In Recurrent Or Metastatic Head And Neck Cancer
23 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
27 Mar 24
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Maintains $21 Price Target
27 Mar 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
27 Mar 24
PDS Biotechnology Q4 EPS $(0.35) Beats $(0.44) Estimate; Cash Balance $56.6M
27 Mar 24